PMC3932807_01
PET-CT in August 2011 (b) shows ~35-40% increase in the size of the LRF mass and appearance of multiple vertebral lesions compared to PET-CT in February 2011 (a), indicating disease progression.
can-8-406fig1.jpg
PMC3932807_01_can-8-406fig1.jpg
figure1
The patient continued therapy for eight cycles until February 2011; however, a routine follow-up PET-CT, six months after discontinuation of therapy, showed a ~35-40% increase in the size of the LRF mass and appearance of multiple vertebral lesions, indicating skeletal metastases, and hence, further disease progression (Figure 1).
PET-CT in November 2011 (b) shows ~50-100% increase in the size of the pulmonary lesions, ~15% increase in the size of the LRF mass, and appearance of new pleural deposits compared to PET-CT in August 2011 (a), indicating disease progression.
can-8-406fig2.jpg
PMC3932807_01_can-8-406fig2.jpg
figure2
PET-CT after initiation of therapy with everolimus and bevacizumab (b) shows a considerable reduction in the size and metabolic activity of the LRF mass, prevascular, right hilar, and retrocrural lymph nodal, pulmonary, and skeletal metastases compared to PET-CT before therapy.
can-8-406fig3.jpg
PMC3932807_01_can-8-406fig3.jpg
figure3
A routine follow-up PET-CT within two months of initiation of therapy with everolimus and Bevacizumab showed a considerable reduction in the size and metabolic activity of the LRF mass, prevascular, right hilar, and retrocrural lymph nodal, pulmonary, and skeletal metastases, indicating a favourable response to therapy with a significant clinical benefit (Figure 3).